AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05243212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-BCMA
Description: CAR-BCMA T-cells are genetically modified autologous T-cells directed to the B-cell maturation antigen (BCMA). CAR-BCMA T-cells identify and eliminate BCMA-expressing malignant plasma cells. Upon binding to BCMA-expressing cells, the CAR transmits a signal to promote T cell expansion, activation, persistence and elimination of malignant plasma cells.
Study NCT04230148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Egaten (Triclabendazole) 250 mg tablets
Description: Egaten 250 mg scored tablets for oral use.
Study NCT05412927 — intervention group
Intervention type: DEVICE
Intervention: PMA P150009 AngelMed Guardian® System
Description: The AngelMed Guardian® System is an implantable cardiac monitor with patient alerting capability and an additional external alarm device. The Guardian® System is indicated for use in patients who have had prior ACS events and who remain at high risk for recurrent ACS events. The Guardian® System is indicated as an adjunct to patient recognized symptoms. The Guardian® System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events.~A Guardian® System alert is a more accurate predictor of ACS events when compared to patient recognized symptoms alone and demonstrates a reduced rate over time of patient presentations without ACS events (false positives) when compared to patient recognized symptoms alone. In the absence of symptoms, the Guardian® System may identify asymptomatic ACS events and prompt the patient to seek medical attention.
Study NCT05052190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Message R/R with Direct Appointment Schedule Link
Description: Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
Study NCT05052190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Message R/R without Direct Appointment Schedule Link
Description: Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
Study NCT05052190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Pre-Appointment Reminder
Description: Participants will receive a Pre-Appointment Reminder via the portal advising them to ask their doctor for the flu vaccine at their upcoming appointment via text when they schedule a visit during the study period.
Study NCT04440748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-Chair 2.0 Prototype
Description: Participants in the experimental group will perform additional therapy with the T-Chair 2.0. Participants can train in two modes. Participants will either train in the active modus, whereby the participant has to move the seat in a certain direction, or in the passive modus, whereby the participant has to stay in a stable position while the seat is moving underneath the participant. The seat is able to move in mediolateral, anteroposterior, and diagonal and combined directions such as circles or eight-figures. The modus, the type of movement, the range of motion and speed of movement are chosen by the therapist according to the patients' abilities.Training will be coupled with a computer based exercise. During the session preparation time, and time for the questionnaires is needed, thus we expect the actual training time to be on average 30 minutes per training.
Study NCT04440748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Rehabilitation Programme
Description: The general rehabilitation program that is offered to all patients of Clinic Valens fits the current standards for treatment post-stroke. This program is tailored to the patients needs and consists of a 90 minute so called focus training per day, which includes physical therapy, occupational therapy, resistance training and gait training. According to the patient needs, extra therapy will be given such as robotic therapy, speech therapy and aquatic therapy. The general rehabilitation program in both groups is comparable in content, time and intensity.
Study NCT04440748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Rehabilitation Programme
Description: The general rehabilitation program that is offered to all patients of Clinic Valens fits the current standards for treatment post-stroke. This program is tailored to the patients needs and consists of a 90 minute so called focus training per day, which includes physical therapy, occupational therapy, resistance training and gait training. According to the patient needs, extra therapy will be given such as robotic therapy, speech therapy and aquatic therapy. The general rehabilitation program in both groups is comparable in content, time and intensity.
Study NCT05523817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation (iTBS)
Description: iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.
Study NCT05523817 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation (iTBS)
Description: iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.
Study NCT05888493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Tisagenlecleucel is a solution for infusion of 0.6 to 6 x 10\^8 CAR-positive viable T-cells taken intravenously (i.v.).
Study NCT05888493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.
Description: Lenalidomide 20 mg daily on days 1-21 for up to 12 cycles Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 2-5
Study NCT05888493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles
Description: Rituximab 375 mg/m2 i.v. on day 1 Cyclophosphamide 750 mg/m2 i.v. day 1 Doxorubicin 50 mg/m2 i.v. day 1 Vincristine 1.4 mg/2 (capped at 2 mg) i.v. day 1 Prednisone or prednisolone 40 mg/m2 PO days 1-5
Study NCT05888493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting chemotherapy
Description: Fludarabine (25 mg/m\^2 intravenously \[i.v.\] daily for 3 doses) OR Cyclophosphamide (250 mg/m\^2 i.v. daily for 3 doses starting with the first dose of fludarabine).~OR Bendamustine 90 mg/m\^2 i.v. daily for 2 days (If there was previous grade IV hemorrhagic cystitis with cyclophosphamide, or the participant demonstrated resistance to a previous cyclophosphamide-containing regimen)
Study NCT05888493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corticosteroids and/or Radiation (Bridging therapy)
Description: Corticosteroids and/or Radiation
Study NCT05693272 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAC-1
Description: Intramuscular vaccine against SARS-CoV-2
Study NCT05693272 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Intramuscular injection of saline placebo
Study NCT06336642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPOT-ON Early Start
Description: Participants will start treatment within 3 days of enrollment, which may include: receiving information on breathing techniques, relaxation techniques, posture techniques, and distraction techniques, and/or trying different oxygen-based therapies, such as high-flow nasal cannula, low-flow supplemental oxygen, and non-invasive ventilation with a respiratory therapist.
Study NCT06336642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPOT-ON Delayed Start
Description: Participants will start treatment within 3 days of enrollment, which may include: receiving information on breathing techniques, relaxation techniques, posture techniques, and distraction techniques, and/or trying different oxygen-based therapies, such as high-flow nasal cannula, low-flow supplemental oxygen, and non-invasive ventilation with a respiratory therapist.
Study NCT05233904 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic-CT-enabled Planning
Description: Diagnostic-CT-enabled planning for patient receiving palliative radiation treatment to bone, soft tissue and lung disease
Study NCT05233904 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients will be booked for CT simulation and treatment as per the local institution's standard practice
Study NCT04785261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylhydroxypropylcellulose
Description: 1-2 drips each time, every 4 hours, for 12 weeks.
Study NCT04785261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylhydroxypropylcellulose
Description: 1-2 drips each time, every 4 hours, for 12 weeks.
Study NCT04785261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbomer
Description: 1 drip each time, at bedtime, for 12 weeks.
Study NCT04785261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbomer
Description: 1 drip each time, at bedtime, for 12 weeks.
Study NCT04785261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM Formula
Description: 6.0g Chi-Ju-Di-Huang-Wan plus 6.0g Jia-Wei-Xiao-Yao-San, 6.0g twice daily for 12 weeks.
Study NCT06570993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cool roof
Description: Cool roofs are a heat-reflecting material that can be applied to existing household roofing in the form of a liquid-applied membrane. Cool roofs work by increasing solar reflectance (the ability to reflect the visible wavelengths of sunlight, reducing heat transfer to the surface) and thermal emittance (the ability to radiate absorbed solar energy) thereby reducing the amount of heat transferred into the home.
Study NCT05893017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exercises
Description: Virtual Reality Exercises will be apply for muscle strengthening
Study NCT05893017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exercises and Kinesiotaping
Description: Virtual Reality Exercises will be apply for muscle strengthening, Kinesiotaping will be applied at Quadriceps muscle and Hamstring muscle
Study NCT05893017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exercises and Valgus Orthoses
Description: Virtual Reality Exercises will be apply for muscle strengthening, Orthoses is for correction at knee alignment
Study NCT05491837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Device induce acute intermittent hypoxia 9 % of Oxygen
Description: Interventional group will be provided a brief sequence of mild hypoxia consisting of 9% oxygen for one minute followed by normoxia 21% of oxygen for a total of 15 episodes
Study NCT05491837 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normoxia 21% of oxygen
Description: SHAM group will be provided normoxia 21% of Oxygen
Study NCT05643807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible cystoscopy
Description: Urinary cytology will be collected through the flexible cystoscope itself at the end the cystoscopy. Before starting the urinary collection, the cystoscope will either be placed in front of a suspected intravesical lesion (if present) or at the bladder neck (if no lesion present).
Study NCT05643807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary catheter
Description: Urinary cytology will be collected through a Ch14 urinary catheter after the cystoscopy
Study NCT05491837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normoxia 21% of oxygen
Description: SHAM group will be provided normoxia 21% of Oxygen
Study NCT05696457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive music therapy
Description: Patients included in the experimental group receive a 25 min passive music therapy session on a daily basis, which changes depending on their emotion.
Study NCT05375448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilisation
Description: Participants will perform an active femoral nerve mobilisation technique. The treatment will be performed at home.~Patients will receive a video model to perform the exercise during the 8 weeks of treatment. The treatment should be performed 10 repetitions twice a day, with one set recommended in the morning and one in the evening.~The treatment will be monitored by telephone and if there are any doubts, the session will be carried out together with the patient.
Study NCT06281535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant loading
Description: Placement of abutments and final restorations either 2 months following implant placement in early loading group or 3 months in conventional loading group
Study NCT06281535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant loading
Description: Placement of abutments and final restorations either 2 months following implant placement in early loading group or 3 months in conventional loading group
Study NCT05142605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning-Centered Grief Therapy
Description: Meaning-Centered Grief Therapy is a therapy that focuses on helping participants find a sense of meaning or purpose in participants' life after participants' loss. Parents will be provided (via mail or email) a workbook. This support program will involve 16 sessions that will take place about once a week. Each session will last 60 to 90 minutes and will be delivered through videoconferencing.
Study NCT05142605 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: Supportive Psychotherapy will help participants cope with participants' loss by giving them a place to express participants' feelings and providing participants with support during the sessions. Supportive counseling will involve 16 sessions that will take place about once a week. Each session will last 60 to 90 minutes and will be delivered through videoconferencing.
Study NCT05142605 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced usual care includes any support or resources participants may receive as part of participants' standard care (for example, therapy sessions with a local therapist), enhanced with additional resources.
Study NCT06039709 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 5-ALA and Low-Intensity Focused Ultrasound (SDT)
Description: 5-ALA (20mg/kg orally) given \~6 hours prior to LIFU. Focused ultrasound will target a maximum of 50% of the tumor.
Study NCT05509803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PE Audit and Feedback Tool
Description: The intervention consists of a Physical Education (PE) Audit and Feedback tool, which was adapted from work done through the PE Works program in the New York City Department of Education. A district-level PE program leader in Oakland Unified School District will deliver the tool, which consists of auditing the current status of PE in intervention schools, providing feedback on the status to help improve PE, and providing technical assistance to bring schools up to code and ensure support for PE programming.
Study NCT05663203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Attend CRCWeb intervention
Study NCT05663203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Complete interview
Study NCT05663203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study NCT05663203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study NCT04999020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Intravenous dosing will consist of a loading dose followed by maintenance doses administered every 8 weeks (q8w). The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
Study NCT04999020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous dosing will consist of a loading dose followed by maintenance doses administered q8w. The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
Study NCT06547775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN069
Description: Solution for SC injection
Study NCT06490133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyhpenol extract
Description: Three capsules in fasting conditions 15 minutes prior breakfast
Study NCT06490133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three capsules in fasting conditions 15 minutes before breakfast
Study NCT05924945 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bridge™ active device
Description: Bridge is a percutaneous nerve field stimulation device
Study NCT05924945 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bridge™ sham device
Description: The sham device has the same appearance and will require the same placement technique as the Bridge (active) device but will not deliver electrical impulses.
Study NCT05583903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Software
Description: The ReCognition virtual reality software is delivered via an Oculus Quest 2 device. This three-dimensional simulated software was designed to improve attention and executive functions.
Study NCT05952648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lower tract respiratory samples
Description: Within 1 hour from HAP or VAP suspicion, quantitative tracheal aspirate or bronchoalveolar lavage will be performed to confirm the diagnosis. Clinicians will be encouraged to perform BAL whenever possible
Study NCT05952648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower tract respiratory samples
Description: Within 1 hour from HAP or VAP suspicion, quantitative tracheal aspirate or bronchoalveolar lavage will be performed to confirm the diagnosis. Clinicians will be encouraged to perform BAL whenever possible
Study NCT05952648 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiplex PCR assay (Film-array Pneumonia Panel Plus)
Description: The lower tract respiratory samples will be analyzed with Multiplex PCR assay (Film-array Pneumonia Plus).
Study NCT05368376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol Hydrochloride Oral Tablet
Description: Labetalol 200 mg
Study NCT05368376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Tartrate Oral Tablet
Description: Metoprolol 100 mg
Study NCT04993937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Interventional group will receive 6 weeks of plyometric training and receive training for week and three sessions in a week.
Study NCT04993937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Control group will follow their daily routine activities and may involve in any other exercise program rather than plyometric exercises.
Study NCT05347173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Dexmedetomidine (10 µg in 0.5 mL normal saline)
Study NCT05347173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Nalbuphine (1 mg in 0.5 mL normal saline)
Study NCT06540690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palatal Wound
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
Study NCT04753931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory Training in addition to Bobath Training
Description: Trunk-focused exercises will be applied for different senses (tactile, proprioceptive, etc.) in addition to Bobath exercises. Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
Study NCT04753931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bobath Training
Description: Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
Study NCT06542393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: * Treatment regimen for hospitalized patients awaiting non-urgent surgeries: Administer EPO 600 IU/kg/week via subcutaneous (SC) or intravenous (IV) route, followed by 300 IU/kg/day via SC or IV 10 days before surgery. If ferritin \< 100 ng/dL, supplement with IV iron (Iron hydroxide up to 600 mg/week or Ferric carboxymaltose up to 1000 mg/week).~* Treatment regimen for hospitalized patients awaiting non-urgent surgeries with less than 5 days until surgery: Administer 40000 UI of EPO intravenous (IV) attack and supplement with IV iron (Iron hydroxide up to 600 mg/week or Ferric carboxymaltose up to 2000 mg/week), then 300UI/Kg/day IV or SC of EPO until day of surgery.